Abstract:Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and immune scores of TCGA glioma tissues were determined using the ESTIMATE algorithm. Differentially expressed genes (DEGs), the protein–protein interaction(PPI) network, and least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were used to select hub genes associated with stroma and immune scores and the prognoses of patients and to construct the risk model. The practicability and specificity of the risk model in both IDH1mt and IDH1-wildtype (wtIDH1) gliomas in TCGA and CGGA were evaluated. Molecular mechanisms, immunological characteristics and benefits of immune checkpoint blockade therapy in glioma tissues with IDH1mt were analyzed using GSEA, immunohistochemical staining, CIBERSORT, and T-cell dysfunction and exclusion (TIDE) analysis. The overall survival rate for IDH1mt-glioma patients with high stroma/immune scores was lower than that for those with low stroma/immune scores. A total of 222 DEGs were identified in IDH1mt glioma tissues with high stroma/immune scores. Among them, 72 genes had interactions in the PPI network, while three genes, HLA-DQA2 , HOXA3 , and SAA2 , were selected as hub genes and used to construct risk models classifying patients into high- and low-risk score groups, followed by LASSO and Cox regression analyses. This risk model showed prognostic value in IDH1mt glioma in both TCGA and CCGA; nevertheless, the model was not suitable for wtIDH1 glioma. The risk model may act as an independent prognostic factor for IDH1mt glioma. IDH1mt glioma tissues from patients with high-risk scores showed more infiltration of M1 and CD8 T cells than those from patients with low-risk scores. Moreover, TIDE analysis showed that immune checkpoint blockade(ICB) therapy was highly beneficial for IDH1mt patients with high-risk scores. The risk model showed specific potential to predict the prognosis of IDH1mt-glioma patients, as well as guide ICB, contributing to the diagnosis and therapy of IDH1mt-glioma patients.

CS-27 * IDH1/2 MUTATIONS INFLUENCE ZEB1 EXPRESSION IN GRADES II AND III GLIOMAS

ZEB1 expression is increased in IDH1- mutant lower-grade gliomas

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

Identification of EMT-associated prognostic features among grade II/III gliomas

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas

Combined epigenetic signature and gene copy number variations in IDH-mutant glioblastomas showed varied risk stratification

Basement-Membrane-Related Gene Signature Predicts Prognosis in WHO Grade II/III Gliomas

Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade

Tmic-26. Immune Cell Dynamics Within Gliomas: The Influence Of Grade And Idh Status

Epco-31. The Germline Polymorphism Rs55705857 Is Associated With A Poor Survival In Astrocytoma, Idh-Mutant, Grade 2

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients

Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced

IDH1 mutation decreases the invasiveness of glioma by downregulating the expression and activity of TAZ

EGFR mutation: a prognostic factor associated with immune infiltration in lower-grade glioma.

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas

Molecular Characterization and Survival Analysis of a Cohort of Glioblastoma, IDH-wildtype